The adeno-associated virus vector manufacturing market is
estimated at USD 1.1 billion in 2024, and a CAGR of 18.6% is expected during
the forecast period. These vectors have the unique property of having a
non-pathogenic nature and the ability to induce long-lasting gene expression.
An increasing number of biotechnology and pharmaceutical firms, and rising
healthcare expenditure on research and development, is driving growth in the
market significantly.
Growing adoption of technologically advanced viral
vectors and rising incidence of carcinoma, along with growing funds for
research and development, are driving growth in the market significantly.
Growing applications of AAV vectors in gene editing and growing use of AAV
vectors in gene delivery of the central nervous system are driving growth in
the market significantly. Continuous Research and Development, and
collaborations among research organizations, academic institutions, and
government agencies are driving growth in the market.

Growth
Drivers
The growing prevalence of genetic disorders and increasing
growth in the aging population worldwide are driving growth in the market.
Technological advancements in the market, and gene editing is driving growth in
the market. Government funding and support are playing a major role in the
market growth significantly. Increasing prevalence of genetic disorders and
rising demand for gene-based therapies are the major driving factors in the
market.
Rising healthcare expenditure and health consciousness among the people
are the key causes behind the significant growth. Increasing demand for vaccine
development, targeted drug delivery, and tissue engineering is driving growth
in the market. Growing demand for gene therapy Advancements in AAV vector
engineering Technological advancements in manufacturing processes Partnerships
and collaborations among market players Increasing government support for gene
therapy research is driving significant growth in the market.
Continuous research and development have resulted in
improved vector design, enhanced transduction efficiency, and scalable
manufacturing processes. Regulatory agencies such as the U.S. FDA and the
European EMA have provided clear guidelines and accelerated approval pathways
for gene therapy products.
Key industry players are forming strategic
collaborations and partnerships to leverage complementary expertise and
resources. Increasing exploration of AAV vectors to treat a myriad of diseases
beyond genetic disorders, including cancer, cardiovascular diseases, and
neurological disorders, is driving growth in the market. These drivers
collectively contribute to the growth of the market significantly.
Segmentation
Therapeutic
Area
·
Hematological Diseases
·
Infectious Diseases
·
Genetic Disorders
·
Neurological Disorders
·
Ophthalmic Disorders
·
Others
By
Application
·
Cell Therapy
·
Gene Therapy
·
Vaccine
By
Operations
·
Clinical
·
Preclinical
·
Commercial
Regional
Outlook
·
Asia Pacific
·
North America
·
Latin America
·
Europe
·
Middle East and Africa
AAV
vectors manufacturing market by therapeutic Area segmentation
On the basis of the therapeutic area, the AAV vectors manufacturing market
is segmented into hematological diseases, infectious diseases, genetic
disorders, neurological disorders, ophthalmic disorders, and others.
Neurological disorders such as Parkinson’s disease and spinal muscular atrophy
represent a significant unmet medical need.

These diseases are often severe and
lack effective treatments, making them prime candidates for gene therapy.
Recent approvals for AAV-based therapies for neurological disorders such as
Zolgensma have demonstrated the feasibility and success of AAV vectors. Global
prevalence of neurological disorders and the high cost associated with their
management are driving the demand in the market significantly. Rising
healthcare expenditure and increasing awareness among the people about the
chronic diseases are driving growth in the market significantly. Increasing
exploration of AAV vectors is driving growth in the market significantly.
AAV vectors
market by application segmentation
On the basis of the application, the AAV vectors manufacturing market is
segmented into cell therapy, gene therapy, and vaccines. Gene therapy is the
leading segment due to the increasing prevalence of genetic disorders and the
demand for effective treatments, which drive investment in gene therapy
applications. Due to a high degree of safety and efficacy, as well as their
ability to target specific cell types in the body.
Gene therapy is by far the
leading segment in the market, and vaccines also hold a significant share in
the AAV vector manufacturing market. AAV vectors do efficiently deliver DNA to
the nucleus. Cell therapy segment is currently smaller, and experiencing
moderate growth in the market, as AAV vectors are increasingly used in
delivering therapeutic genes to patient cells. Increasing exploration of AAV
vectors, which are helpful in the treatment of various diseases, is the key
factor behind the significant growth.
Regional
Outlook
On the basis of the regions, the AAV vectors manufacturing market is
segmented into 5 regions: Asia Pacific, North America, Latin America, the
Middle East and Africa, and Europe. North America is currently the leading
market in AAV vectors, due to the presence of major pharmaceuticals and
biotechnology companies, along with numerous research institutions, which is
spurring the market growth significantly. North America has a vibrant ecosystem
of collaboration and partnerships among research organizations, academic
institutions, and biopharmaceutical companies.
These collaborations are helpful
in technology transfer and resource access. The region’s well-established
healthcare infrastructure supports the development and adoption of advanced
therapies, including those utilizing AAV vectors. Rising healthcare
expenditure, rising awareness about advanced therapeutic solutions, and growing
prevalence of genetic disorders: countries like China and India are emerging as
significant players with substantial investment in biotechnology and gene
therapy research. Europe has a robust pipeline of gene therapies targeting
various diseases including rare genetic disorders, and cancers.

Surge in gene
therapy development necessitates efficient viral vector production. Increasing
adoption of advance technologies in bioprocessing, automation, and analytical
tools, enhancing the efficiency and quality of viral vector. Germany leads the
AAV vector market due to increased investments, and technological advancements
in manufacturing processes. Presence of key players in European region is the
primary reason behind the significant market growth. Middle East and Africa,
and Latin America are witnessing significant market growth due to increasing
awareness among the people about the gene therapy. Rising healthcare
expenditure, and increasing awareness among the people about the diseases is
driving growth in the market.
Key
Players
·
F. Hoffman-La Roche Ltd.
·
Children’s Hospital of Philadelphia
·
Takeda Pharmaceuticals
·
Bayer AG
·
Novartis AG
·
Pfizer Inc.
·
REGENXBIO
·
Oxford Biomedical PLC
·
Bluebird bio
·
AAVexis
·
UniQure
·
Sanofi
·
Singamo Therapeutics
·
Other Players
Specifications |
Descriptions |
No Specifications |